<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6342">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027468</url>
  </required_header>
  <id_info>
    <org_study_id>EK 548/2009</org_study_id>
    <nct_id>NCT01027468</nct_id>
  </id_info>
  <brief_title>Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration</brief_title>
  <official_title>Functional, Morphological And Safety Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration - 3 Years Of Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      200 eyes with each subtype of neovascular age-related macular degeneration will be included
      in this study and 3 years after the initial intravitreal bevacizumab, best-corrected visual
      acuity (BCVA) will be measured using Snellen charts at 6m. Central retinal thickness (CRT)
      will be measured using Stratus OCT and Cirrus SD-OCT (Zeiss). Data of treatment-naive eyes
      (group 1) were compared to the data of eyes that had undergone prior treatment with
      photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide (group 2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this interventional clinical study, 181 eyes of 160 consecutive patients with active
      neovascular related macular degeneration meeting recommended criteria for inclusion and
      protocol criteria for anti-vascular endothelial growth factor therapy undergoing
      intravitreal bevacizumab monotherapy were evaluated. Data of treatment-naive eyes (Group 1,
      n = 114) were analyzed separately from eyes that had undergone previous photodynamic therapy
      plus intravitreal triamcinolone (Group 2, n = 67). Re-treatment criteria were based on
      clinical outcome following the official European label regimen. After 1 year of continuous
      service at an academic referral center, follow-up was performed in private practices in
      collaboration with the referral center. Main outcome parameters were best-corrected visual
      acuity and central retinal thickness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Vision</measure>
    <time_frame>3 years after first intravitreal bevacizumab treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Vision</measure>
    <time_frame>3 years after initial intravitreal bevacizumab treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic Complications After Treatment, Central Retinal Thickness</measure>
    <time_frame>3 years after initial bevacizumab treatment</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>bevacizumab intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>intraocular bevacizumab injection</description>
    <arm_group_label>group 1</arm_group_label>
    <other_name>intraocular injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  any subtype of neovascular age-related macular degeneration

          -  age of 50 years or older

          -  initial treatment with intravitreal bevacizumab between August 2005 and June 2006

        Exclusion Criteria:

          -  previous vitrectomy

          -  presence of cystoid macular edema without choroidal neovascularization

          -  Uncontrolled sytemic disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Sacu, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Medical University of Vienna, Austria</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 7, 2014</lastchanged_date>
  <firstreceived_date>December 7, 2009</firstreceived_date>
  <firstreceived_results_date>January 7, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Stefan Sacu</investigator_full_name>
    <investigator_title>Assoc. Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>bevacizumab, choroidal neovascularization</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Medical University of Vienna, Department of Ophthalmology during September 2008-July 2009 with a mean of 3 year follow-up after initial Bevacizumab intravitreal treatment</recruitment_details>
      <pre_assignment_details>Inclusion criteria:
patients treated with bevacizumab due to wet age-related macular degeneration
follow-up of 3 years
Exclusion criteria:
- patients with other macular diseases</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>3 year follow-up of patients with intravitreal application of bevacizumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>3 year follow-up of intravitreal application of bevacizumab</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="160"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="77.24" spread="10.56"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="102"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="58"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Vision</title>
        <time_frame>3 years after first intravitreal bevacizumab treatment</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>3 year follow-up of intravitreal application of bevacizumab</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="160"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Vision</title>
            <units>logMar</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.16" spread="0.21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vision</title>
        <time_frame>3 years after initial intravitreal bevacizumab treatment</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Complications After Treatment, Central Retinal Thickness</title>
        <time_frame>3 years after initial bevacizumab treatment</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>3 year follow-up of intravitreal application of bevacizumab</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>intraocular inflammation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Assoc.Prof.PD.Dr.Stefan Sacu</name_or_title>
      <organization>Medical University of Vienna</organization>
      <phone>+43404001 ext 7937</phone>
      <email>stefan.sacu@meduniwien.ac.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
